Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 457-463

  Jung, Kyoung In ^a   Kim, Jie Hyun ^a   Park, Hae Young Lopilly ^a   Park, Chan Kee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROTECTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; GLUCOSE BLOOD LEVEL; IMMUNOFLUORESCENCE; NERVE CELL LESION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA GANGLION CELL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CELL DEATH; DIABETIC RETINOPATHY; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL FIBRILLARY ACIDIC PROTEIN; IN SITU NICK-END LABELING; ISCHEMIA; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED OLETF; RETINA; RETINAL GANGLION CELLS; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878052802     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203067     Document Type: Article

References (48)

1. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, and Geboes K (2004) Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci 45:2760-2766.
2. Ahmed J, Braun RD, Dunn R, Jr, and Linsenmeier RA (1993) Oxygen distribution in the macaque retina. Invest Ophthalmol Vis Sci 34:516-521.
3. Aizu Y, Oyanagi K, Hu J, and Nakagawa H (2002) Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology 22:161-170.
4. Ajjan RA and Grant PJ (2011) The role of antiplatelets in hypertension and diabetes mellitus. J Clin Hypertens (Greenwich) 13:305-313.
5. Angiolillo DJ (2009) Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32:531-540.
6. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, and LaNoue KF, et al.; JDRF Diabetic Retinopathy Center Group (2006) Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 55:2401-2411.
7. Antonetti DA, Klein R, and Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227-1239.
8. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, and Lorenzi M (2003) A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52:506-511.
9. Bai Y, Ma JX, Guo J, Wang J, Zhu M, Chen Y, and Le YZ (2009) Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol 219: 446-454.
10. Barber AJ (2003) A new view of diabetic retinopathy: A neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283-290.
11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, and Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783-791.
12. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, and Ratner RE, et al.; ACTION I Investigator Group (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40.
13. Chapman TM and Goa KL (2003) Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 3:117-138.
14. Cheung N, Mitchell P, and Wong TY (2010) Diabetic retinopathy. Lancet 376: 124-136.
15. Cheung N and Wong TY (2008) Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res 27:161-176.
16. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, and Vignati L; PKC-DRS2 Study Group (2009) Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 50:1-4.
17. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611.
18. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, 3rd, and Klein R American Diabetes Association (2003) Diabetic retinopathy. Diabetes Care 26:226-229.
19. Geng DF, Deng J, Jin DM, Wu W, and Wang JF (2012) Effect of cilostazol on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials. Atherosclerosis 220:177-183.
20. Hillegass WB, Brott BC, Dobbs JC, Papapietro SE, Misra VK, and Zoghbi GJ (2011) Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: An overview. Vasc Health Risk Manag 7:445-459.
21. Hiller R, Sperduto RD, Podgor MJ, Ferris FL, 3rd, and Wilson PW (1988) Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study. Am J Epidemiol 128:402-409.
22. Ikeda Y (1999) Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82:435-438.
23. Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K, Kiryu J, and Yoshimura N (2007) Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. J Thromb Haemost 5:818-825.
24. Kashimoto R, Kurimoto T, Miyoshi T, Okamoto N, Tagami Y, Oono S, Ito Y, and Mimura O (2008) Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 436:116-119.
25. Katakami N, Kim YS, Kawamori R, and Yamasaki Y (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: A randomized trial. Circulation 121:2584-2591.
26. Kihara M, Schmelzer JD, and Low PA (1995) Effect of cilostazol on experimental diabetic neuropathy in the rat. Diabetologia 38:914-918.
27. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, and Kim JS (2005) Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36:782-786.
28. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY, and Lee WS (2006) Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 1082:182-191.
29. Miller JW, Adamis AP, and Aiello LP (1997) Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 13:37-50.
30. Mina A, Favaloro EJ, and Koutts J (2007) Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: A comprehensive meta-review. Semin Thromb Hemost 33:798-809.
31. Natarajan A, Zaman AG, and Marshall SM (2008) Platelet hyperactivity in type 2 diabetes: Role of antiplatelet agents. Diab Vasc Dis Res 5:138-144.
32. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, and Orchard TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 169:1307-1316.
33. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, and Adamis AP, et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67.
34. O'Callaghan JP (1991) Assessment of neurotoxicity: Use of glial fibrillary acidic protein as a biomarker. Biomed Environ Sci 4:197-206.
35. Osborne NN and Larsen AK (1996) Antigens associated with specific retinal cells are affected by ischaemia caused by raised intraocular pressure: Effect of glutamate antagonists. Neurochem Int 29:263-270.
36. Pournaras CJ (1995) Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Retina 15:332-347.
37. Schäfer A and Bauersachs J (2008) Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 6:52-60.
38. Shindo H, Tawata M, and Onaya T (1993) Cyclic adenosine 39,59-monophosphate enhances sodium, potassium-adenosine triphosphatase activity in the sciatic nerve of streptozotocin-induced diabetic rats. Endocrinology 132:510-516.
39. Shiraishi Y, Kanmura Y, and Itoh T (1998) Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca21]i and force in middle cerebral artery of the rabbit. Br J Pharmacol 123:869-878.
40. Sima AA, Zhang WX, Cherian PV, and Chakrabarti S (1992) Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat. Diabetologia 35:602-607.
41. Simó R, Carrasco E, García-Ramírez M, and Hernández C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98.
42. Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clinic Proc 87:77-88.
43. Suehiro A SY, Masuda H, and Kakishita E (1993) A study of the effects of cilostazol on platelet function and serum lipids in patients with diabetes mellitus. Curr Ther Res 54:553-561.
44. Thompson PD, Zimet R, Forbes WP, and Zhang P (2002) Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314-1319.
45. Wang F, Li M, Cheng L, Zhang T, Hu J, Cao M, Zhao J, Guo R, Gao L, and Zhang X (2008) Intervention with cilostazol attenuates renal inflammation in streptozotocininduced diabetic rats. Life Sci 83:828-835.
46. Wangsa-Wirawan ND and Linsenmeier RA (2003) Retinal oxygen: Fundamental and clinical aspects. Arch Ophthalmol 121:547-557.
47. Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D, and Dinardo JA (2009) The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg 108:1425-1429.
48. Zhang X, Bao S, Hambly BD, and Gillies MC (2009) Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 41:2368-2371.